3 not yet recruiting, 2 unknown, 1 completed. 3 Phase 4, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Not applicable | 2 | Not yet recruiting 1, Unknown 1 |
Follow Yanbing Li: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial Mazdutide, Placebo - Diabetes Mellitus, Type 2 | Not applicable | Not yet recruiting | Yanbing Li | 249 | 2026-09-30 | 2026-08-17 |
| Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes CSII, Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin Degludec and Insulin Aspart Injection - Type 2 Diabetes | Phase 4 | Not yet recruiting | Yanbing Li | 324 | 2026-03-15 | 2026-02-06 |
| Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes Cofrogliptin add to insulin, Linagliptin add to insulin - Type 2 Diabetes | Not yet recruiting | Yanbing Li | 594 | 2025-10-01 | 2025-09-30 | |
| Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes Chiglitazar sodium, Chiglitazar placebo - Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients, Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect | Not applicable | Unknown | Yanbing Li | 128 | 2023-10-31 | 2023-09-13 |
| Impact of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification CSII and thereafter combination therapy, followed up with wearable devices, CSII and thereafter combination therapy, Basal insulin treatment without wearables - Diabetes type2 | Phase 4 | Completed | Yanbing Li | 276 | 2019-05-01 | 2026-09-08 |
| A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy Linagliptin, Humalog Mix 75/25 - Type 2 Diabetes Mellitus, Peritoneal Dialysis | Phase 4 | Unknown | Yanbing Li | 232 | 2017-06-03 | 2017-10-24 |
Diabetes Mellitus, Type 2 (4) · Insulin Resistance (1)
Insulin Glargine (1) · Linagliptin (1) · Metformin (1) · Wearable Electronic Devices (1) · insulin degludec, insulin aspart drug combination (1) · insulin lispro, isophane insulin lispro drug combination (25:75) (1) · mazdutide (1)
China (5)